Avalo Therapeutics AVTX Free cash flow
Discontinued — last reported Q4 '24
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The official record: Avalo Therapeutics’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's free cash flow?
- Avalo Therapeutics (AVTX) reported free cash flow of -$15.04M in Q4 2024.
- How has Avalo Therapeutics's free cash flow changed year-over-year?
- Avalo Therapeutics's free cash flow decreased by 443.9% year-over-year, from -$2.77M to -$15.04M.
- What is the long-term trend for Avalo Therapeutics's free cash flow?
- Over 2 years (2021 to 2024), Avalo Therapeutics's free cash flow has grown at a -16.9% compound annual growth rate (CAGR), from -$71.01M to -$49.06M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.